Clinical Trial

Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
To evaluate the safety and efficacy of autologous hematopoietic stem cell transplantation (ASCT) combined with BCMA-CART in the treatment of UHR-MM.
Trial Details
NCT Number NCT07109323
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Collaborators: Hebei Taihe Chunyu Biotechnology Co., Ltd
Conditions Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions, Cytogenetics Ultra High Risk, Primary Refractory, Early Progression, Plasma Cell Leukemia, Non Paraosseous Extramedullary Infiltration, R2-ISS-IV /MPSS-IV
Enrollment 50 participants
Start Date 2025-03-03
Primary Completion 2028-03-02 (estimated)
Study Completion 2030-03-02 (estimated)
Updated on ClinicalTrials.gov 2025-08-07